Colorectal Cancer
Sep 01, 2026
Takeda’s MIMRYLO Wins U.S. FDA Approval for Polycythemia Vera; Lilly’s Mounjaro Gains FDA Approval for Cardiovascular Risk Reduction in Type 2 Diabetes; Teva Expands Neuroscience Portfolio Through Proposed Acquisition; BioNTech Ends Phase 2 Study of Autogene Cevumeran in Colorectal Cancer; AusperBio Secures $120 Million Series C to Advance AHB-137 and Next-Generation Hepatitis B Therapies
Takeda Gains FDA Approval for MIMRYLO Takeda announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for MIMRYLO™ (rusfertide) to treat erythrocytosis in adults with polycythemia vera (PV), a type of blood cancer. MIMRYLO is a first-in-class hepcidin mimetic develop...
Read More...
Jul 14, 2026
Hengrui Pharma Encounters FDA Regulatory Hurdle for Camrelizumab–Rivoceranib; Kailera Therapeutics Announces Positive Results for HRS-7535/KAI-7535 Across Two Phase 3 Studies; Jemperli Underscores Durable Clinical Complete Responses in dMMR/MSI-H Rectal Cancer; FDA Approves PADCEV-Keytruda Combination for Neoadjuvant and Adjuvant Treatment of Muscle-Invasive Bladder Cancer; Sanofi’s Subcutaneous Sarclisa Escena Gains US Approval
Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab–Rivoceranib Combination in Advanced Liver Cancer Hengrui Pharma and Elevar Therapeutics have encountered another setback in their efforts to secure U.S. approval for the combination of camrelizumab and rivoceranib, as the FDA has issued a thir...
Read More...
Jun 02, 2026
Hanmi Pharmaceutical and Eli Lilly and Company Join Forces to Advance Sonefpeglutide Development; Johnson & Johnson’s ERLEADA Achieves Positive Phase 3 Outcomes; Revolution Medicines Unveils Landmark Phase 3 RASolute 302 Data Demonstrating Strong Efficacy of Daraxonrasib in Metastatic Pancreatic Cancer; Pfizer’s BRAFTOVI Treatment Advances Outcomes by Nearly Doubling Progression-Free Survival in mCRC; Imfinzi Sets a New Standard with US Approval of the Only Immunotherapy Combination for BCG-Naïve High-Risk Bladder Cancer
Hanmi Pharmaceutical Secures Licensing Agreement with Eli Lilly and Company for Sonefpeglutide Hanmi Pharmaceutical announced a licensing agreement with Eli Lilly and Company covering the development, manufacturing, and commercialization of sonefpeglutide (LAPSGLP-2 analog), Hanmi’s investigational biologi...
Read More...
Nov 06, 2025
From Science Fiction to Reality: Investigating the Market Dynamics and Growing Demand for the Smart Pills
Over the past few years, the evolution of smart pills has been remarkable, driven largely by advancements in smart pills technology and innovative developments in healthcare. These smart pills, equipped with sensors, microprocessors, and wireless communication capabilities, have revolutionized the field of medicine...
Read More...
Aug 20, 2025
ENHERTU’s Rapid Rise: How the HER2-Targeting ADC Is Redefining Cancer Treatment with Back-to-Back Label Expansions
ENHERTU, a next-generation antibody-drug conjugate (ADC) jointly developed by Daiichi Sankyo/ AstraZeneca since March 2019, except in Japan, where Daiichi Sankyo maintains exclusive rights. It is worth noting that recently, in November 2024, Daiichi Sankyo and AstraZeneca were awarded the Galien Foundation 2024 Pri...
Read More...
Apr 29, 2025
Boston Scientific Pushes Forward Despite $200M Tariff Challenge; Northstrive Biosciences Gets FDA Green Light to Advance EL-22 Obesity Trial; Roche Acts Swiftly to Offset U.S. Tariff Impact with Global Engagements; Verastem Oncology Secures IND Clearance for KRAS G12D Inhibitor Trial; BlackfinBio Gets FDA OK for Phase I/II Trial of BFB-101 in SPG47
Boston Scientific Pushes Forward Despite $200M Tariff Challenge Boston Scientific has announced that tariffs are expected to add approximately $200 million to its costs this year, but the company remains confident in its ability to absorb the financial hit. Despite the tariff burden, the company reported robust ...
Read More...
Nov 27, 2024
AI in Cancer Diagnostics: Paving the Way for Early Detection and Precision Treatment
Artificial Intelligence (AI) is revolutionizing numerous fields, and healthcare, particularly cancer diagnostics, is no exception. With the promise of faster, more accurate diagnoses, AI is transforming how clinicians detect, diagnose, and treat cancer. By leveraging vast amounts of medical data, advanced algorithm...
Read More...
Oct 22, 2024
Gilead and Merck Announce Encouraging Phase II Results of Islatravir and Lenacapavir Combo; REGENXBIO Highlights Positive Data from Phase II ABBV-RGX-314 Wet AMD Study at AAO 2024; FDA Greenlights Astellas’ VYLOY for Advanced Gastric and GEJ Cancer Therapy; Merck’s CAPVAXIVE Vaccine Yields Strong Immune Response in Adults Vulnerable to Pneumococcal Disease; FDA Postpones LUMAKRAS Colorectal Cancer Verdict to Early 2025
Gilead and Merck Reports Phase II Data Showing that Switching to a Once-Weekly Oral Combination of Islatravir and Lenacapavir Maintained Viral Suppression in Adults Through 48 Weeks Gilead Sciences, Inc. and Merck have shared new findings from a Phase II clinical trial assessing the experimental combination of i...
Read More...
Oct 04, 2024
7 Companies at the Forefront of Trispecific Antibody Development
Trispecific antibodies are the next frontier in targeted cancer therapy, offering a powerful new approach to treating complex diseases. These innovative antibodies are designed to bind to three different antigens simultaneously, enhancing treatment precision. By engaging multiple targets at once, trispecific antibo...
Read More...
Oct 02, 2024
Gastrointestinal Cancers: Exploring the Range of Digestive Tract Malignancies
With millions of cases diagnosed globally each year, gastrointestinal cancers represent a significant health challenge but also an opportunity for breakthroughs in targeted therapies and personalized medicine. Gastrointestinal cancers refer to a group of cancers that affect the digestive system, including the esoph...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
